The First Half of 2015 Was a Huge Win for Biotech Investors: Here Are the Top Picks of the Top Stock Pickers for Q3 & Q4

WINDSOR, ON / ACCESSWIRE / July 30, 2015 / The Wealthy Biotech Trader, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech stocks making news and subsequent market moves, announced today some trade ideas for the second half of 2015 – biotech stocks hand-picked by some of finance’s biggest experts. These guys won big in the first half of the year, so why not keep the train rolling?

As evidenced by the fact that most retail investors do not yet know about how much money is being made in this sector, we feel things are just getting started and nowhere close to a bubble. But form your own assumptions after reading this.

Healthcare/ biotech started its secular bull market in March of 2009 much like the overall market, but The Nasdaq Biotech Index (NASDAQ:IBB) has returned a stunning 550% return in only 6 1/2 years which pales in comparison to the overall market (the S&P 500) over the same timeframe, which has only returned 180%. It’s important to note that by taking the advice of seasoned, expert stock pickers and activist investors who invest with their own billions, traders could have made returns far in excess of these as there are many winners in this universe. Here are a few stocks in the space we have hand-selected based on hard evidence of huge potential success.

PositiveID Corporation (OTC: PSID), a developer of biological detection and diagnostics solutions, this week announced its goals for the second half of 2015, which focus on the continued development and testing of the Firefly Dx prototype PCR (polymerase chain reaction) pathogen detection system that is targeting the $27 billion global PCR market. The Company is targeting to report revenue in excess of $3 million for 2015, compared to revenue of $945,000 for 2014. The full press release can be reviewed here: Aside from the 217% increase in revenue year over year, we are extremely keen on this stock because of their Firefly Dx product under development.

(PSID)’s Firefly Dx, once developed, would be a one-of-a-kind handheld device that can take a blood/saliva sample or meat/produce sample and test it and provide lab-quality results within 20 minutes to see if the sample is infected with a contagious disease or the food is contaminated. This type of testing can currently only be done in a lab, is not practical, and is time consuming taking four hours or more, only after it has been transported to the lab. This would be a hand-held/ portable, cost-effective lab that first responders, doctors, military, food processors (among many others) could all use to prevent epidemics of disease and dangerous contaminated food getting into our food supply. To our knowledge no other companies are attempting this, and PositiveID (PSID) is heavily protecting their work/intellectual property with many patents. This could be a multi-billion dollar sales product on its own, in our opinion. The Company could be commercially selling Firefly Dx next year, which is really not that far as stocks tend to move in anticipation of events such as this.

Three other biotech companies worth watch-listing for the coming days, weeks or months are as follows:

Recro Pharma, Inc. (REPH) is our most compelling play for the second half of the year and 2016. The main reason is because very recently a hedge fund called Broadfin Capital made a large Investment in the company just weeks ago (other institutional investors are all over this one as well). Broadfin is run by the very wealthy and successful Kevin Kotler. We won’t get into Mr. Kotler’s employment past which is filled with A+ financial positions with the biggest and most successful financial firms on Wall Street. All in all, the reason this is all notable is that Mr. Kotler’s fund is the third best performing fund in’s whole database. Smart traders follow the smart money.

Aside from this, we feel REPH’s stock chart is insanely bullish looking and seems like it could run much further. We typically wouldn’t say a chart is ripe for entry after a 1,000% annualized move, but REPH’s market cap is quite small at roughly $100 million. As for what the science of the Company is working on (it’s quite comical that we’re mentioning this last), Recro Pharma, Inc., is a clinical stage specialty pharmaceutical company, engaged in developing non-opioid therapeutics for the treatment of pain. This is a hot-button topic with rampant abuse of painkillers, which is literally ruining a lot of lives, and a suitable non-opioid substitute would benefit society greatly.

Another great story is BioSpecifics Technologies Corp. (BSTC). BSTC was recently mentioned as one of the 10 best biotech stocks for 2015 on BSTC has another great chart, but investors may want to wait for a pull-back to enter. BSTC is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for 12 clinical indications to date.

Next we would like to update on an old time favorite: Advaxis (ADXS). Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. We like Immunotherapy, we like Oncology companies, and we like ADXS’s chart and the hype that’s come along with it. When we first started to report on ADXS on June 16, 2015, we thought the chart looked like it needed a correction. Since then the stock has retraced from $30 to as low as $15.50. This could represent a nice Fibonacci retracement level of support, and if it holds, it could be an attractive entry point for traders – but be careful!

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.


Follow us on Twitter: @Wealthy_VC

Like us on Facebook:


This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a “safe harbor” in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements.” Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

The Wealthy Biotech Trader’s parent company has been and will continue to be compensated $25,000 per month by PositiveID. The Wealthy Biotech Trader’s controlling parent company has also been compensated $62,500 by PositiveID in the form of a convertible note and readers should understand that they will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed.

Readers must visit our website at in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this art.

SOURCE: The Wealthy Biotech Trader

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

pour la musculation tamoxifen buylivraison anonyme, prix favorable As a rule, the infection occurs during penetrative sexual intercourse buy metronidazole no prescription moist environment and can remain viable. cialis 20mg rezeptfreider Wirkstoff des Arzneimittels wird nicht verlassen, Zweifel an der Wirksamkeit der Pillen ein bewährtes Medikament zur Behandlung von BPH in einer Dosierung von 10 mg, die Möglichkeit gibt, ein neues Potential des Penis, um zu versuchen buy Retin AThis drug will no doubt help to solve the problem with acne in young people from 16 years, thanks to the active ingredient of this cream you will experience relief, people will stop laughing at you Diagnosticare la causa della disfunzione erettilecomprar cilaiscosì spesso il trattamento può comportare molteplici tecniche. Comprar cialis en línea

Wealthy Venture Capitalist